Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review

Sumitomo Dainippon Pharma Co Ltd (4506) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co Ltd develops manufactures, purchases, sells, imports and exports pharmaceutical products. The company focuses on major therapeutic areas which include central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. It also offers veterinary products, research materials, food additives, chemical product materials, food ingredients, diagnostic agents, cosmetic materials and other products. Sumitomo Dainippon has research laboratories, manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan.

Sumitomo Dainippon Pharma Co Ltd Key Recent Developments

May 21,2020: Sumitovant Biopharmas family of companies achieve multiple clinical and corporate milestones in the first full quarter of Sumitovants operation
Dec 30,2019: Urovant Sciences enters into $300 million term loan agreement with Sumitomo Dainippon Pharma
Dec 30,2019: Myovant Sciences announces closing of $400 million loan facility, repayment of debt, board of director transitions, and executive promotions
Dec 03,2019: Sumitomo Dainippon Pharma becomes a global partner to Plug and Plays Innovation Platform
Nov 27,2019: Sumitomo Dainippon Pharma announces organizational realignment and changes in executive officers and other key positions

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Sumitomo Dainippon Pharma Co Ltd - Key Facts
Sumitomo Dainippon Pharma Co Ltd - Key Employees
Sumitomo Dainippon Pharma Co Ltd - Key Employee Biographies
Sumitomo Dainippon Pharma Co Ltd - Major Products and Services
Sumitomo Dainippon Pharma Co Ltd - History
Sumitomo Dainippon Pharma Co Ltd - Company Statement
Sumitomo Dainippon Pharma Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Sumitomo Dainippon Pharma Co Ltd - Business Description
Business Segment: Other Business
Overview
Performance
Business Segment: Pharmaceuticals Business
Overview
Performance
Geographical Segment: China
Performance
Geographical Segment: Japan
Performance
Geographical Segment: North America
Performance
Geographical Segment: Other Regions
Performance
R&D Overview
Sumitomo Dainippon Pharma Co Ltd - Corporate Strategy
Sumitomo Dainippon Pharma Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Sumitomo Dainippon Pharma Co Ltd - Strengths
Sumitomo Dainippon Pharma Co Ltd - Weaknesses
Sumitomo Dainippon Pharma Co Ltd - Opportunities
Sumitomo Dainippon Pharma Co Ltd - Threats
Sumitomo Dainippon Pharma Co Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
May 21, 2020: Sumitovant Biopharmas family of companies achieve multiple clinical and corporate milestones in the first full quarter of Sumitovants operation
Dec 30, 2019: Urovant Sciences enters into $300 million term loan agreement with Sumitomo Dainippon Pharma
Dec 30, 2019: Myovant Sciences announces closing of $400 million loan facility, repayment of debt, board of director transitions, and executive promotions
Dec 03, 2019: Sumitomo Dainippon Pharma becomes a global partner to Plug and Plays Innovation Platform
Nov 27, 2019: Sumitomo Dainippon Pharma announces organizational realignment and changes in executive officers and other key positions
Sep 06, 2019: Sumitomo Dainippon and Roivant form $3bn alliance
Jul 09, 2019: Sumitomo Dainippon Pharma and National Center for Global Health and Medicine initiate international project on measures against antimicrobial resistance (AMR) and promote the proper use of antibiotics in Vietnam
May 10, 2019: Sumitomo Dainippon Pharma announces Changes in Board of Directors
May 08, 2019: Sumitomo Dainippon Pharma to Open a New Office for its Regenerative Medicine/Cell Therapy Business in San Diego, U.S.
Apr 11, 2019: Sumitomo Dainippon Pharma announces mid-term business plan 2022
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Sumitomo Dainippon Pharma Co Ltd, Key Facts
Sumitomo Dainippon Pharma Co Ltd, Key Employees
Sumitomo Dainippon Pharma Co Ltd, Key Employee Biographies
Sumitomo Dainippon Pharma Co Ltd, Major Products and Services
Sumitomo Dainippon Pharma Co Ltd, History
Sumitomo Dainippon Pharma Co Ltd, Other Locations
Sumitomo Dainippon Pharma Co Ltd, Subsidiaries
Sumitomo Dainippon Pharma Co Ltd, Key Competitors
Sumitomo Dainippon Pharma Co Ltd, Ratios based on current share price
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...1)
Sumitomo Dainippon Pharma Co Ltd, Annual Ratios (Cont...2)
Sumitomo Dainippon Pharma Co Ltd, Interim Ratios
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sumitomo Dainippon Pharma Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures

 
Sumitomo Dainippon Pharma Co Ltd, Performance Chart (2016 - 2020)
Sumitomo Dainippon Pharma Co Ltd, Ratio Charts
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sumitomo Dainippon Pharma Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Sumitomo Annual Review Outlook Strategic

2024 Sumitomo Annual Review and Outlook--Strategic SWOT Analysis, Performance, Capabilities, Goals and Strategies in the Global Chemicals Industry This report is part of the Competitive Analysis Series, which

USD 750 View Report

Sumitomo Bakelite Co Ltd (4203) - Strategic SWOT Analysis Review

Sumitomo Bakelite Co Ltd (4203) - Strategic SWOT Analysis Review provides a comprehensive insight into the companys history, corporate strategy, business structure and operations. The report contains a detailed SWOT

USD 125 View Report

Sumitomo Dainippon Pharma Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Sumitomo Dainippon Pharma Co., Ltd. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportMarketlines Sumitomo Dainippon Pharma Co., Ltd. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

USD 350 View Report

Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report

Sumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance ReportSumitomo Dainippon Pharma Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data

USD 175 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available